Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

2024376 citationsJournal Article

Authors

Linda‐Gail Bekker · Centre for the AIDS Programme of Research in South Africa

Moupali Das · Centre for the AIDS Programme of Research in South Africa

Quarraisha Abdool Karim · Centre for the AIDS Programme of Research in South Africa

Khatija Ahmed · Centre for the AIDS Programme of Research in South Africa

Joanne Batting · Centre for the AIDS Programme of Research in South Africa

William Brumskine · Centre for the AIDS Programme of Research in South Africa

Abstract

No participants receiving twice-yearly lenacapavir acquired HIV infection. HIV incidence with lenacapavir was significantly lower than background HIV incidence and HIV incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 1 ClinicalTrials.gov number, NCT04994509.).

Topics & Keywords

HIV/AIDS Research and Interventions HIV-related health complications and treatments Adolescent Sexual and Reproductive Health

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: New England Journal of Medicine

Volume 391, Issue 13, pp. 1179-1192

DOI: 10.1056/nejmoa2407001

Field-Weighted Citation Impact: 145.06